ArticleRedox report : communications in free radical research2025
Dynamic redox monitoring in differentiated human neuroblastoma models of Parkinson's disease.
Article in Redox report : communications in free radical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundOxidative stress plays a critical role in the degeneration of midbrain dopaminergic (DA) neurons in Parkinson's disease (PD). However, therapies targeting redox mechanisms are hindered by a lack of scalable and inexpensive redox-focused preclinical models.
methodsWe stably expressed the glutathione-specific redox-sensitive fluorescent protein Grx-roGFP2 in SH-SY5Y and BE(2)-M17 neuroblastoma cell lines. We developed an improved differentiation protocol using staurosporine and dbcAMP to enhance dopaminergic-like characteristics, assessed by DA marker expression, and characterized responses to PD-relevant toxins.
resultsBE(2)-M17 cells expressed higher DA markers than SH-SY5Y cells, and the improved protocol further increased DA markers. Differentiated neuroblastoma cells with dopaminergic-like features showed greater sensitivity to MPP+ and paraquat, with reduced viability, increased oxidative stress, glutathione oxidation, decreased TH expression, and altered neuronal morphology, paralleling patterns observed in PD-related oxidative injury. roGFP2 enabled robust, real-time redox monitoring, correlating oxidative stress with phenotype. Sublethal toxin exposure caused mitochondrial alterations and redox shifts. Pretreatment with N-acetyl-L-cysteine (NAC) mitigated oxidative stress, improved viability, and partially restored TH expression and morphology.
conclusionThis neuroblastoma-based model with dopaminergic-like features enables scalable, real-time redox monitoring and detailed phenotypic analyses. It expands access to redox biology platforms for investigating neurodegeneration and evaluating antioxidant therapeutic strategies relevant to neurodegeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.